Loading
A phase 2 trial of JNJ-79635322 in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07266441 by Janssen Research & Development, LLC, with 157 participants planned, started 2026-02-08 and due to reach its primary completion in 2027-06-14. Interventions recorded: JNJ-79635322. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/